PCN3 Quality-Adjusted Survival in Patients With Wild-Type (WT) KRASs Metastatic Colorectal Cancer (mCRC) Receiving First-Line Therapy With Panitumumab Plus FOLFOX Versus FOLFOX AloneJ. Wang, Jean‐Yves Douillard, Beth Sherrill et al.|Value in Health|2012Cited by 0
Quality-Adjusted Survival in Patients with Wild-Type (WT) Kras Metastatic Colorectal Cancer (MCRC) Receiving First-Line Therapy with Panitumumab Plus Folfox Versus Folfox AloneJ. Wang, Jean‐Yves Douillard, Zhongyun Zhao et al.|Annals of Oncology|2012Cited by 0